FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2399530872> ?p ?o ?g. }

• W2399530872 endingPage "1833" @default.
• W2399530872 startingPage "1833" @default.
• W2399530872 abstract "Abstract Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) are systemic histiocytic disorders characterized by infiltration of histiocytes in multiple tissues of the body leading to organ compromise. Although the underlying etiology of these conditions has long been enigmatic, recent investigations have determined that LCH and ECD are clonal disorders of myeloid-derived precursor cells with a high frequency of BRAFV600E mutations (40-60% of patients). Moreover, treatment of BRAF-mutant LCH and ECD patients with the BRAF inhibitor vemurafenib has demonstrated dramatic efficacy. The above data underline the importance of accurately identifying BRAF mutational status in patients with systemic LCH and ECD. Unfortunately, the scant histiocyte content and marked stromal contamination, which are a hallmark of these disorders, make mutation detection in tissue biopsies challenging. Moreover,the propensity of histiocytic lesions to involve difficult to biopsy locations frequently necessitates the use of bone biopsies further limiting the availability of suitable tumor material for BRAF genotyping. We therefore initiated a prospective, blinded, multicenter study of BRAFV600E mutation detection in the cell-free DNA (cfDNA) from plasma and urine of histiocytosis patients to determine the sensitivity/specificity of cfDNA mutation detection compared with tissue biopsy and to track disease burden serially with therapy. Between January 2013 and June 2014, 30 consecutive patients with ECD (n=25) and LCH (n=5) were enrolled from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Initial BRAF tissue mutation testing on tissue biopsies was performed by a variety of methods as part of routine care in CLIA-certified molecular diagnostic laboratories. We applied a droplet-digitial PCR assay (RainDrop ddPCR) for quantitative detection of the BRAFV600E mutation in plasma and urine cell-free cfDNA in all patients. Of 30 patients enrolled, initial tissue BRAFV600E genotyping identified 15 patients to be mutant, 6 patients as wildtype, and 9 as indeterminate. There was 100% concordance between tissue and urinary cfDNA genotype in samples from treatment naïve patients (sensitivity 92.9%, specificity 100%, positive predictive value 100%, negative predictive value 85.7% compared to tissue biopsy detection). Urinary cfDNA analysis identified 5 patients as being BRAFV600E mutant that were not known to have the BRAF mutation previously (Figure A). Subsequent tissue biopsy was performed in 2 of these patients and identified the BRAFV600E mutation, allowing both patients to enroll in an ongoing phase II study of vemurafenib. Results from plasma cfDNA for identifying the BRAFV600E mutation were comparable to urinary cfDNA results Next examining serial samples during therapy, a significant decrease in the cfDNA BRAFV600E:BRAF wildtype ratio was seen with therapy compared with pretreatment samples (p<0.0001). In all 10 patients treated with a BRAF inhibitor, serial urinary cfDNA analysis revealed progressive decrements in the BRAFV600E allele burden. Weekly serial urinary cfDNA analysis throughout the course of BRAF inhibitor therapy revealed that the decline in mutant cfDNA burden in response to BRAF inhibitors was consistent with radiographic disease improvement (Figure B). Moreover, in at least one patient where successful RAF inhibitor therapy was discontinued for toxicity, urinary cfDNA BRAFV600E burden increased after vemurafenib discontinuation which mirrored radiographic evidence of disease recurrence. Finally, 2 patients treated with the IL1-receptor antagonist anakinra exhibited substantial decreases in BRAFV600E burden, highlighting an effect of IL-1 receptor antagonism in BRAF-mutant histiocytes. These results indicate that cfDNA BRAFV600E mutational analysis in plasma and urine provides a convenient and reliable method of detecting mutational status and can serve as a non-invasive biomarker to monitor response to therapy in LCH and ECD. Moreover, the dynamic results achieved with cfDNA analysis allowed for monitoring of disease recurrence with treatment cessation. Of note, this study represents the largest prospective study of adult ECD patients to date. Moreover, these data represent the first evidence of the effect of RAF inhibition as well as IL1-receptor antagonism on the BRAF mutant clone in patients with histiocytosis. Figure 1 Figure 1. Disclosures Vibat: Trovagene Inc.: Employment. Hassaine:Trovagene Inc.: Employment. Poole:Trovagene Inc.: Employment. Lu:Trovagene Inc.: Employment. Erlander:Trovagene Inc.: Employment. Janku:Trovagene Inc.: Consultancy, Research Funding." @default.
• W2399530872 created "2016-06-24" @default.
• W2399530872 creator A5001079998 @default.
• W2399530872 creator A5003109423 @default.
• W2399530872 creator A5011012477 @default.
• W2399530872 creator A5024369304 @default.
• W2399530872 creator A5025595346 @default.
• W2399530872 creator A5038444859 @default.
• W2399530872 creator A5053263729 @default.
• W2399530872 creator A5053481267 @default.
• W2399530872 creator A5065440606 @default.
• W2399530872 creator A5068193017 @default.
• W2399530872 creator A5071800834 @default.
• W2399530872 creator A5073486774 @default.
• W2399530872 creator A5074326774 @default.
• W2399530872 creator A5076426660 @default.
• W2399530872 creator A5077063317 @default.
• W2399530872 creator A5082806411 @default.
• W2399530872 creator A5085026927 @default.
• W2399530872 creator A5085101229 @default.
• W2399530872 date "2014-12-06" @default.
• W2399530872 modified "2023-10-18" @default.
• W2399530872 title "Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders" @default.
• W2399530872 doi "https://doi.org/10.1182/blood.v124.21.1833.1833" @default.
• W2399530872 hasPublicationYear "2014" @default.
• W2399530872 type Work @default.
• W2399530872 sameAs 2399530872 @default.
• W2399530872 citedByCount "1" @default.
• W2399530872 countsByYear W23995308722016 @default.
• W2399530872 crossrefType "journal-article" @default.
• W2399530872 hasAuthorship W2399530872A5001079998 @default.
• W2399530872 hasAuthorship W2399530872A5003109423 @default.
• W2399530872 hasAuthorship W2399530872A5011012477 @default.
• W2399530872 hasAuthorship W2399530872A5024369304 @default.
• W2399530872 hasAuthorship W2399530872A5025595346 @default.
• W2399530872 hasAuthorship W2399530872A5038444859 @default.
• W2399530872 hasAuthorship W2399530872A5053263729 @default.
• W2399530872 hasAuthorship W2399530872A5053481267 @default.
• W2399530872 hasAuthorship W2399530872A5065440606 @default.
• W2399530872 hasAuthorship W2399530872A5068193017 @default.
• W2399530872 hasAuthorship W2399530872A5071800834 @default.
• W2399530872 hasAuthorship W2399530872A5073486774 @default.
• W2399530872 hasAuthorship W2399530872A5074326774 @default.
• W2399530872 hasAuthorship W2399530872A5076426660 @default.
• W2399530872 hasAuthorship W2399530872A5077063317 @default.
• W2399530872 hasAuthorship W2399530872A5082806411 @default.
• W2399530872 hasAuthorship W2399530872A5085026927 @default.
• W2399530872 hasAuthorship W2399530872A5085101229 @default.
• W2399530872 hasConcept C126322002 @default.
• W2399530872 hasConcept C142724271 @default.
• W2399530872 hasConcept C2775934546 @default.
• W2399530872 hasConcept C2777484599 @default.
• W2399530872 hasConcept C2779134260 @default.
• W2399530872 hasConcept C2780174970 @default.
• W2399530872 hasConcept C43100952 @default.
• W2399530872 hasConcept C71924100 @default.
• W2399530872 hasConceptScore W2399530872C126322002 @default.
• W2399530872 hasConceptScore W2399530872C142724271 @default.
• W2399530872 hasConceptScore W2399530872C2775934546 @default.
• W2399530872 hasConceptScore W2399530872C2777484599 @default.
• W2399530872 hasConceptScore W2399530872C2779134260 @default.
• W2399530872 hasConceptScore W2399530872C2780174970 @default.
• W2399530872 hasConceptScore W2399530872C43100952 @default.
• W2399530872 hasConceptScore W2399530872C71924100 @default.
• W2399530872 hasIssue "21" @default.
• W2399530872 hasLocation W23995308721 @default.
• W2399530872 hasOpenAccess W2399530872 @default.
• W2399530872 hasPrimaryLocation W23995308721 @default.
• W2399530872 hasRelatedWork W2009657118 @default.
• W2399530872 hasRelatedWork W2045451178 @default.
• W2399530872 hasRelatedWork W2078886881 @default.
• W2399530872 hasRelatedWork W2083233500 @default.
• W2399530872 hasRelatedWork W2103701567 @default.
• W2399530872 hasRelatedWork W2138392777 @default.
• W2399530872 hasRelatedWork W244065325 @default.
• W2399530872 hasRelatedWork W2462823902 @default.
• W2399530872 hasRelatedWork W3129510299 @default.
• W2399530872 hasRelatedWork W3194971048 @default.
• W2399530872 hasVolume "124" @default.
• W2399530872 isParatext "false" @default.
• W2399530872 isRetracted "false" @default.
• W2399530872 magId "2399530872" @default.
• W2399530872 workType "article" @default.